Skip to main content

Belzutifan Approved for Advanced Renal Cell Carcinoma

The FDA has approved belzutifan (Welireg™, Merck & Co., Inc.) for advanced renal cell carcinoma (RCC) subsequent to a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).   Why it matters: "Belzutifan is a first-in-class oral hypoxia-inducible factor 2alpha (HIF-2α) inhibitor approved in the US for patients with Von Hippel-Lindau disease–associated RCC, primitive neuroectodermal t...

Continue reading